Diakonos Oncology Announces Final Closing of Oversubscribed $11.4M Seed Financing to Advance Its Highly Differentiated Dendritic Cell Vaccine (DOC1021) into a Phase 2 Clinical Trial
August 26, 2024 05:30 AM Eastern Daylight Time HOUSTON–(BUSINESS WIRE)–Diakonos Oncology Corp., a clinical-stage immuno-oncology company, announced today the final closing of an oversubscribed seed financing of $11.4 million. The round was led by biotechnology…